These findings suggest that ZDHHC9 expression may alter the tumor immune microenvironment (TIME) in BC, transforming it from an immune-active state to an immune-inhibited one, thereby impacting cancer prognosis and responses to immunotherapy. This evidence concerns the gene ZDHHC9 and breast cancer.